INOVIO PHARMACEUTICALS, INC. 8-K

What Happened

• Inovio Pharmaceuticals, Inc. (INO) filed a Form 8-K (Item 2.02) on July 29, 2026, reporting a preliminary, unaudited estimate of its cash and cash equivalents of approximately $36.7 million as of June 30, 2026. The company said this figure is based on management’s preliminary estimates and is not a complete statement of results for the quarter ended June 30, 2026.

Key Details

• Preliminary cash and cash equivalents: approximately $36.7 million as of June 30, 2026.
• Data is preliminary and unaudited; subject to completion of quarter-end closing procedures and may change.
• Ernst & Young LLP did not audit, review, examine, compile, or apply agreed-upon procedures to the preliminary data and expresses no assurance.
• The 8-K disclosure is furnished (not “filed”) and includes forward-looking statement cautions and references to the company’s other SEC filings (prospectus supplement dated July 29, 2026; Form 10-Q for quarter ended March 31, 2026; Form 10-K for year ended December 31, 2025).

Why It Matters

• Cash and cash equivalents are a key measure of liquidity and short-term runway for a clinical-stage biotech. The reported $36.7M gives investors a snapshot of Inovio’s available cash at quarter end, but because the figure is preliminary and unaudited, investors should wait for the finalized quarterly financial statements (and management discussion) for a complete picture.
• The filing’s disclaimer about audit and potential changes highlights that the final results could differ; investors should monitor forthcoming filings (the completed 10-Q or other SEC reports) for confirmed figures and any related operational or financing updates.